VFA
BPMC

Valeo Financial Advisors’s Blueprint Medicines BPMC Stock Holding History

Valeo Financial Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11
Closed -$1K – 1795
2019
Q4 		$1K Hold
11
– – ﹤0.01% 1518
2019
Q3 		$1K Buy
+11
New +$951 ﹤0.01% 1439

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Valeo Financial Advisors's BPMC Position: Q1 2020 in Review

Valeo Financial Advisors sold out of Blueprint Medicines (BPMC) in Q1 2020, closing a stake of 11 shares — an estimated $1K sold.

Valeo Financial Advisors first reported a position in BPMC in Q3 2019 and held it in 2 quarters. The position peaked at $1K in Q4 2019. 213 funds tracked by Wall St. Rank hold BPMC as of Q1 2020.

  • Valeo Financial Advisors reported no remaining Blueprint Medicines position as of Q1 2020 after selling out during the quarter.
  • Valeo Financial Advisors sold 11 Blueprint Medicines shares in Q1 2020, an estimated $1K.
  • Valeo Financial Advisors first reported a position in Blueprint Medicines in Q3 2019 and held it in 2 quarters.
  • Valeo Financial Advisors's Blueprint Medicines position peaked at $1K in Q4 2019.
  • 213 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2020.

Based on Valeo Financial Advisors's 13F filing for Q1 2020, filed 13 Apr 2020.